The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,733.50
Bid: 1,732.50
Ask: 1,733.00
Change: 0.00 (0.00%)
Spread: 0.50 (0.029%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 1,733.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

London close: US debt uncertainty persists, Footsie finishes under

Mon, 25th Jul 2011 16:42

The Footsie trimmed earlier gains as markets in the US recovered after a weak start. Despite falling as low as 5,893 on Monday, London's blue chip index finished firmly above the 5,900 mark, as giants BP, ARM, BG and GlaxoSmithKline rose ahead of their interim results due tomorrow. While stocks on Wall Street took a hit after the opening bell, the retreat wasn't as bad as many had expected, even though the nation is only eight days from a possible default. Investors continued "to call Washington's bluff" in regards to the debt ceiling talks, according to CNNMoney, which suggested that investors do not believe that government officials will allow the US to default on its debt.Meanwhile, the euro crisis raged on after ratings agency Moody's downgraded Greece's sovereign debt rating by three notches from Caa1 to Ca, a mere two stations above a rating that would signify a default. Investors are concerned that Spain and even Italy could be next in the firing line. Back in London on the FTSE 100, silver producer Fresnillo finished as a high riser on the back of a rising silver price, which increased by 0.74% to $40.42 at 16:44. Gold prices edged upwards also, as nervousness over the US debt talks boosted the safe-haven appeal of precious metals.The banks were among the worst performers as volatility in the sector continues amidst the ongoing euro crisis. Banking shares rallied on Thursday after European leaders agreed a new aid package for Greece and an overhaul of the Eurozone sovereign rescue fund. However, Barclays, RBS and Lloyds were all lower today as a result of concern about the future of the single currency. Insurers Aviva, Resolution, Admiral and Standard Life were also among the heavy fallers.Sector peers Melrose and Charter International were rising after Melrose said today that it is thinking over whether or not to up its bid for Charter after the target dismissed its first two offers. "Melrose is willing to consider increasing its proposal to reflect any information which demonstrates that it has materially undervalued Charter and justifies such an increase," the firm said. Dixons Retail was a heavy faller on the FTSE 250 after UBS downgraded the electricals retailer from "neutral" to "sell", saying that trading is "set to remain tougher for longer". The Swiss broker thinks that Dixons, which owns PC World and Currys, is likely to report a weak first quarter "given the tough World Cup comparative [of last year] but we expect [the second half] to remain tough". Leading the risers was pizza delivery group Domino's Pizza, after it posted a sharp rise in first-half profits in the first half of the year despite the tough economic climate. BCFTSE 100 - RisersFresnillo (FRES) 1,729.00p +2.86%Weir Group (WEIR) 2,210.00p +2.55%United Utilities Group (UU.) 598.00p +1.70%GlaxoSmithKline (GSK) 1,363.50p +1.68%Burberry Group (BRBY) 1,600.00p +1.39%Capital Shopping Centres Group (CSCG) 386.10p +1.39%Reckitt Benckiser Group (RB.) 3,526.00p +1.38%GKN (GKN) 238.20p +1.15%BG Group (BG.) 1,425.00p +1.10%Hammerson (HMSO) 477.10p +1.10%FTSE 100 - FallersBarclays (BARC) 228.95p -4.44%Lloyds Banking Group (LLOY) 45.10p -4.30%Aviva (AV.) 412.60p -3.01%Resolution Ltd. (RSL) 281.90p -2.32%Hargreaves Lansdown (HL.) 596.00p -2.05%Admiral Group (ADM) 1,562.00p -2.01%Autonomy Corporation (AU.) 1,662.00p -1.71%Cairn Energy (CNE) 386.80p -1.58%Royal Bank of Scotland Group (RBS) 36.28p -1.57%Vodafone Group (VOD) 162.00p -1.55%
More News
17 Dec 2023 15:16

PRESS: GSK looks for deals in China as rebuilds relationship

(Alliance News) - The Financial Times on Sunday reported that GSK PLC is looking for some new deals in China.

Read more
15 Dec 2023 17:08

European shares end fifth week higher on rate-cut optimism

Barclays sees first ECB rate cut in April

*

Read more
15 Dec 2023 16:51

LONDON MARKET CLOSE: FTSE 100 underperforms as post-Fed rally cools

(Alliance News) - London's FTSE 100 ended lower on Friday, with profit-taking and some hawkish words from a US policymaker keeping equities in check at the end of a largely positive week for stocks.

Read more
15 Dec 2023 16:29

PRESS: GSK, Astra and AbbVie in US scrutiny over patents - Bloomberg

(Alliance News) - A US senator has accused AstraZeneca PLC, GSK PLC, AbbVie Inc and other drugmakers of "abusing" the patent system to send prices higher, Bloomberg reported on Thursday.

Read more
12 Dec 2023 10:08

AstraZeneca buys respiratory vaccine developer Icosavax in $1.1 bln deal

Dec 12 (Reuters) - AstraZeneca said on Tuesday it had agreed to buy respiratory syncytial virus (RSV) vaccine developer Icosavax in a deal valued at up to $1.1 billion.

Read more
12 Dec 2023 08:22

TOP NEWS: Japan accepts GSK's filing for respiratory disease vaccine

(Alliance News) - GSK PLC on Tuesday said Japan's Ministry of Health, Labour & Welfare has accepted its regulatory application for the extension of its respiratory syncytial virus vaccine, Arexvy, for adults aged 50-59.

Read more
12 Dec 2023 07:39

LONDON BRIEFING: UK unemployment unchanged at 4.2%; eyes on US CPI

(Alliance News) - Stocks in London are called to open higher, as investors digest the latest UK unemployment data, before turning their heads to US inflation.

Read more
12 Dec 2023 07:24

GSK seeks to extend RSV vaccine approval in Japan

(Sharecast News) - GSK announced on Tuesday that Japan's Ministry of Health, Labour and Welfare (MHLW) has accepted its regulatory application for the extension of the indication of its RSV vaccine to include adults aged 50- to 59 at an increased risk of contracting the disease.

Read more
11 Dec 2023 08:28

GSK drug gets EU marketing backing for form of endometrial cancer

(Alliance News) - GSK PLC on Monday said it won EU backing for its Jemperli drug in tandem with chemotherapy to treat a form of endometrial cancer.

Read more
11 Dec 2023 07:41

LONDON BRIEFING: GSK drug gets EU endorsement; Begbies backs outlook

(Alliance News) - London's FTSE 100 is called to open a touch lower on Monday, kicking off the week with some slight trepidation after Friday's hotter-than-expected US jobs report which offered the dollar some respite.

Read more
11 Dec 2023 07:23

GSK endometrial cancer treatment gets Europe authorisation

(Sharecast News) - GSK announced on Monday that the European Commission has granted marketing authorisation for 'Jemperli', or dostarlimab, in combination with chemotherapy for certain endometrial cancers.

Read more
7 Dec 2023 12:54

THG backer Kelso pushes for demerger to trim "inherent" valuation gap

(Alliance News) - THG PLC investor Kelso Group Holdings PLC on Thursday reiterated its call for a demerger, which the shareholder believes will help close the "disparity" between the e-commerce firm's share price and its true value.

Read more
5 Dec 2023 10:02

LONDON BROKER RATINGS: Goldman lifts Landsec and British Land

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
27 Nov 2023 09:00

GSK announces positive results from Blenrep phase 3 blood cancer trial

(Alliance News) - GSK PLC on Monday said a phase 3 trial of belantamab mafodotin as a multiple myeloma treatment has produced positive headline results.

Read more
27 Nov 2023 08:02

GSK receives 'positive' headline results from phase III trial

(Sharecast News) - Drugmaker GSK announced on Monday that it had received positive headline results from a planned interim efficacy analysis from a phase III trial evaluating its elantamab mafodotin asset.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.